CPR Pharma Services Pty Ltd (CPR) is the only Australian CRO to combine clinical and data management services with a GLP-accredited, FDA-inspected laboratory. Due to the high efficiency of the Australian regulatory framework, CPR’s Fast2PhaseOne service enables clients to make fast “Go/No Go” decisions for their First-in-Human trials. CPR’s Immunoassay Service utilizes SECTOR Imager 2400 in support of preclinical and clinical studies for monoclonal antibodies, biologics, and biosimilars. John Chappell heads CPR’s Immunoassay Group, bringing with him over 20 years of experience from leading CROs in Europe and North America. CPR provides clients with a full-service offering in the Asia-Pacific region.